UDD Logo
CRIS - Current Research Information System
New user? Click here to register.Have you forgotten your password?
Communities & Collections
Research Outputs
Fundings & Projects
Researchers
Datasets
Statistics
  1. Home
  2. CRIS
  3. Publications
  4. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
Details

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Journal
JAMA Oncology
ISSN
2374-2437
Date Issued
2020
Author(s)
Kohei Shitara
Eric Van Cutsem
Yung-Jue Bang
Charles Fuchs
Lucjan Wyrwicz
Keun-Wook Lee
Iveta Kudaba
Marcelo Garrido
Hyun Cheol Chung
Jeeyun Lee
Hugo Raul Castro
Wasat Mansoor
Maria Ignez Braghiroli
Nina Karaseva
Christian Caglevic
Facultad de Medicina Clínica Alemana Universidad del Desarrollo  
Luis Villanueva
Eray Goekkurt
Hironaga Satake
Peter Enzinger
Maria Alsina
Al Benson
Joseph Chao
Andrew H. Ko
Zev A. Wainberg
Uma Kher
Sukrut Shah
S. Peter Kang
Josep Tabernero
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85091456614
WoS ID
WOS:000583209400011
DOI
10.1001/jamaoncol.2020.3370
URL
https://investigadores.udd.cl/handle/123456789/4737
Subjects
adult

; 

aged

; 

aged, 80 and over

; 

antibodies, monoclonal, humanized

; 

antineoplastic combined chemotherapy protocols

; 

esophagogastric junction

; 

female

; 

humans

; 

male

; 

middle aged

; 

stomach neoplasms

; 

young adult

; 

capecitabine

; 

cisplatin

; 

fluorouracil

; 

pembrolizumab

; 

antineoplastic agent

; 

monoclonal antibody

; 

pembrolizumab

; 

adult

; 

advanced cancer

; 

aged

; 

alopecia

; 

anemia

; 

antineoplastic activity

; 

article

; 

asthenia

; 

cancer chemotherapy

; 

cohort analysis

; 

constipation

; 

controlled study

; 

decreased appetite

; 

dehydration

; 

diarrhea

; 

dizziness

; 

drug efficacy

; 

drug safety

; 

dry skin

; 

dysgeusia

; 

fatigue

; 

female

; 

follow up

; 

human

; 

hyperpigmentation

; 

hypokalemia

; 

hypomagnesemia

; 

hypothyroidism

; 

leukopenia

; 

major clinical study

; 

male

; 

mucosa inflammation

; 

nausea

; 

neutropenia

; 

overall survival

; 

peripheral neuropathy

; 

phase 3 clinical trial

; 

progression free survival

; 

pruritus

; 

randomized controlled trial

; 

rash

; 

sensory neuropathy

; 

side effect

; 

stomach cancer

; 

stomatitis

; 

thrombocytopenia

; 

tinnitus

; 

vomiting

; 

clinical trial

; 

gastroesophageal junction

; 

middle aged

; 

mortality

; 

pathology

; 

stomach tumor

; 

very elderly

; 

young adult
Logo Universidad de Desarrollo
Encuéntranos en:

Sede Santiago

Av. Plaza 680, Las Condes

Contacto|Mapa

Sede Concepción

Ainavillo 456, Concepción

Contacto|Mapa

Hosting & SupportLogo Scimago Lab

Built with DSpace-CRIS software - Extension maintained and optimized by 4science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify